15546 Background: Peritoneal dissemination of appendiceal neoplasms (AN) is traditionally treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) with a reported median 10-yr overall survival (OS) of 50–60%. Treatment options are limited for those who are not optimal candidates for CRS. We have previously shown that systemic chemotherapy may help in selected patients (Shapiro et al; ASCO GI, 2007); however, the role for biologic agents has not been characterized in these poor prognosis patients. Increased vascular endothelial growth factor (VEGF) expression in tissue specimens has recently been associated with poor prognosis. The purpose of this study was to evaluate the role of biologic agents in patients who were not candidates for cytoreduction. Methods: A retrospective observational cohort study was conducted of AN pts who received systemic chemotherapy with anti-VEGF (bevacizumab) or anti-epidermal growth factor receptor-targeted therapy (cetuximab, panitumumab,...